Menu Search
Equities

Corcept Therapeutics Inc

CORT:NAQ

Corcept Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)59.60
  • Today's Change5.30 / 9.76%
  • Shares traded1.73m
  • 1 Year change+131.37%
  • Beta0.5178
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Corcept Therapeutics Inc grew revenues 20.04% from 401.86m to 482.38m while net income improved 4.66% from 101.42m to 106.14m.
Gross margin98.44%
Net profit margin22.56%
Operating margin22.81%
Return on assets20.58%
Return on equity25.77%
Return on investment25.10%
More ▼

Cash flow in USDView more

In 2023, Corcept Therapeutics Inc increased its cash reserves by 104.36%, or 69.22m. The company earned 127.04m from its operations for a Cash Flow Margin of 26.34%. In addition the company generated 90.91m cash from investing, though they paid out 148.72m more in financing than they received.
Cash flow per share1.28
Price/Cash flow per share43.68
Book value per share6.12
Tangible book value per share6.12
More ▼

Balance sheet in USDView more

Corcept Therapeutics Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio3.70
Quick ratio3.64
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 8.61%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)9.80
EPS (TTM) vs
TTM 1 year ago		56.02
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.